Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong Min Liu
臺北市立萬芳醫院
研究成果: 雜誌貢獻 › 回顧型文獻 › 同行評審
Introduction: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. Areas covered: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. Expert opinion: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.
Expert Opinion on Investigational Drugs
已發佈 - 十月 2 2016
指紋 深入研究「Investigational glucagon-like peptide-1 agonists for the treatment of obesity」主題。共同形成了獨特的指紋。
Glucagon-Like Peptide-1 Receptor Medicine & Life Sciences
Glucagon-Like Peptide 1 Medicine & Life Sciences
Obesity Medicine & Life Sciences
Liraglutide Medicine & Life Sciences
Nausea Medicine & Life Sciences
Expert Testimony Medicine & Life Sciences
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z. M. (2016). Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs, 25(10), 1167-1179. https://doi.org/10.1080/13543784.2016.1221925
Investigational glucagon-like peptide-1 agonists for the treatment of obesity. / Tomlinson, Brian; Hu, Miao; Zhang, Yuzhen; Chan, Paul; Liu, Zhong Min.
於: Expert Opinion on Investigational Drugs, 卷 25, 編號 10, 02.10.2016, p. 1167-1179.
Tomlinson, B, Hu, M, Zhang, Y, Chan, P & Liu, ZM 2016, 'Investigational glucagon-like peptide-1 agonists for the treatment of obesity', Expert Opinion on Investigational Drugs, 卷 25, 編號 10, 頁 1167-1179. https://doi.org/10.1080/13543784.2016.1221925
Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs. 2016 10月 2;25(10):1167-1179. https://doi.org/10.1080/13543784.2016.1221925
Tomlinson, Brian ; Hu, Miao ; Zhang, Yuzhen ; Chan, Paul ; Liu, Zhong Min. / Investigational glucagon-like peptide-1 agonists for the treatment of obesity. 於: Expert Opinion on Investigational Drugs. 2016 ; 卷 25, 編號 10. 頁 1167-1179.
@article{15e81b3565e0486c9f5d7ea1bea42bdf,
title = "Investigational glucagon-like peptide-1 agonists for the treatment of obesity",
abstract = "Introduction: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. Areas covered: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. Expert opinion: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.",
keywords = "Efpeglenatide, GLP-1 receptor agonist, ITCA 650, exenatide, liraglutide, obesity, semaglutide",
author = "Brian Tomlinson and Miao Hu and Yuzhen Zhang and Paul Chan and Liu, {Zhong Min}",
note = "Publisher Copyright: {\textcopyright} 2016 Informa UK Limited, trading as Taylor & Francis Group. Copyright: Copyright 2016 Elsevier B.V., All rights reserved.",
journal = "Expert Opinion on Investigational Drugs",
T1 - Investigational glucagon-like peptide-1 agonists for the treatment of obesity
AU - Tomlinson, Brian
AU - Hu, Miao
AU - Zhang, Yuzhen
AU - Chan, Paul
AU - Liu, Zhong Min
N1 - Publisher Copyright: © 2016 Informa UK Limited, trading as Taylor & Francis Group. Copyright: Copyright 2016 Elsevier B.V., All rights reserved.
N2 - Introduction: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. Areas covered: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. Expert opinion: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.
AB - Introduction: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. Areas covered: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. Expert opinion: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.
KW - Efpeglenatide
KW - GLP-1 receptor agonist
KW - ITCA 650
KW - exenatide
KW - liraglutide
KW - obesity
KW - semaglutide
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs